Companies & Industry »Company News
Dr Reddys Laboratories Ltd - Company News

BSE   18 Aug 17 | 12:00 AM

1982.90 -27.1 (-1.35%)
Mkt Price (Rs)   Chg Rs (Chg %)
Code: 500124
Face Value: 5

NSE   18 Aug 17 | 12:00 AM

1982.00 -29.25 (-1.45%)
Mkt Price (Rs)   Chg Rs (Chg %)
Code: DRREDDY
Performance
1 Week : Rs 2,011.35 (-1.41%)
1 Month : Rs 2,746.10 (-27.79%)
1 Year : Rs 3,011.25 (-34.15%)
change companytradenow

  • 31 Jul 17
    06:08 AM
    After facing a “perfect storm&" of adverse developments, Dr Reddy’s Laboratories expects a better performance this fiscal year, with cost reductions and new product launches.
  • 12 May 17
    03:53 PM
    Indian pharmaceutical major Dr Reddy's Laboratories Limited has reported a three-fold increase in consolidated net profit at Rs 312.5 crore for the quarter that ended on March 2017 as compared to Rs 74 crore in the corresponding quarter previous year.
    10:48 AM
    Dr Reddy’s Laboratories hit 52-week low of Rs 2,554 on BSE in intra-day trade ahead of its January-March quarter (Q4FY17) results today.
  • 22 Mar 17
    10:15 AM
    Shares of two pharmaceutical companies Dr Reddy's Laboratories and Divi's Laboratories continued to trade under pressure, hitting an over two-year lows on BSE amid US drug regulator concerns.
  • 10 Mar 17
    12:34 AM
    In another setback to drug major Dr Reddy’s Laboratories’ (DRL’s) remediation effort, its oncology formulations facility at Duvvada in Visakhapatnam has got a long and adverse rap from the US Food and Drug Administration (FDA).
  • 09 Mar 17
    09:28 AM
    Dr Reddy's Laboratories has fallen to its 52-week low of Rs 2,751, down 3.5% on BSE in early morning trade after the US Food and Drug Administration (FDA) made 13 observations at the company’s formulations facility at Duvvada in Visakhapatnam.
  • 22 Feb 17
    05:00 AM
    Dr Reddy’s Laboratories on Tuesday informed the stock exchanges the US Food and Drug Administration (US FDA) had made three adverse observations with a Form 483, after completing an audit of its active ingredients (APIs) manufacturing facility at
  • 11 Nov 16
    03:26 PM
    Dr Reddy's laboratories announced on Friday that it has launched Raloxifene hydrochloride tablets in 60 mg, a therapeutic equivalent generic version of Evista tablets in the United States market, following the approval from US Food and Drug Administration
  • 27 Oct 16
    10:41 AM
    Dr Reddy’s Laboratories have moved higher to three-months high of Rs 3,307, up 2% on the BSE in on otherwise weak market, after the company announced new strategic deal with Gland Pharma in the US market.
  • 10 Oct 16
    05:44 PM
    Dr Reddy's Laboratories announced today that it has launched Lamotrigine Orally Disintegrating Tablets in 25 mg, 50 mg, and 200 mg in the US market following the approval from the US Food and Drug Administration (USFDA).
  • 16 Sep 16
    04:34 PM
    Dr Reddy's Laboratories Limited announced today that it has expanded its strategic collaboration with Amgen, one of the world's leading independent biotechnology companies, to market and distribute three of Amgen's medicines in India in the therapy areas
  • 29 Aug 16
    02:55 PM
    Dr Reddy's Laboratories Limited on Monday announced that it has launched Nitroglycerin sublingual tablets USP, 0.3 mg, 0.4 mg and 0.6 mg, a therapeutic equivalent generic version of Nitrostat in the US market on August 26, following the approval from the
1|2|3|4|5|6|7|8|Next
Widgets Magazine

Sensex

Company Price Gain (%)
Hind. Unilever1,199.702.13
Power Grid Corpn222.851.55
TCS2,512.851.32
Bharti Airtel421.601.21
ITC281.800.84
Widgets Magazine

Online Portfolio

You can create Online Portfolio here using the below button.

Widgets Magazine